NL-OMON53234招募中不适用
TrEatment Targets in Rheumatoid Arthritis: a randomized multi-centre, treat to target strategy trial: TETRA study - TETRA
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 340
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Diagnosis of RA (according to the 2010 ACR/ EULAR classification criteria
- •and/or clinical diagnosis)
- •- Aged 16 years or older
- •- At most low disease activity, operationalised as DAS28-CRP <3.5 (DAS28 CRP
- •2.9 cut off for low disease activity with measurement error 0.6) or SDAI < 19
- •(SDAI 11 cut off for low disease activity with measurement error 8) or the
- •rheumatologist*s opinion. A state of low disease activity is required at
- •inclusion, as for RA patients in moderate or high disease activity there is no
- •equipoise on the best course of action (treatment needs to be escalated, both
- •in case of aiming for remission or LDA).
- •- Fluency of Dutch or English, both written and verbally; able to fill in
- •questionnaires
- •- Provided informed consent
排除标准
- •- Clinical deep remission, operationalised as SDAI <3.3 or DAS28-CRP
- •<2.4, AND a taper attempt in the past 2 years that was discontinued due to
- •occurrence of flare.
- •- Fewer than 3 DMARD treatment options left for this patient (severe
- •difficult-to-treat or refractory RA)
- •- Current severe comorbidity or other serious life-shortening conditions
- •hampering trial participation
- •- Inability to comply with the study protocol or to provide informed consent
- •with regard to intervention control and measuring outcomes
研究者
相似试验
进行中（未招募）
不适用
TrEatment Targets in Rheumatoid Arthritis: TETRA-studyRheumatoid ArthritisNCT06046950Sint Maartenskliniek340
已完成
不适用
Treatment strategies for Rheumatoid Arthritis (BeSt - BehandelStrategieën in Reumatoïde Artritis)Musculoskeletal DiseasesArthropathiesRheumatoid arthritisISRCTN32675862eiden University Medical Centre (LUMC) (Netherlands)508
招募中
不适用
TApering strategies in Rheumatoid Arthritis remission induced by anti-TNF&classic DMARDs. Should we taper the classic DMARD or anti-TNF first?rheumatoid arthritisrheumatism10023213NL-OMON41388Erasmus MC, Universitair Medisch Centrum Rotterdam355
已完成
不适用
BIOmarker-driven DEcision Study with Adalimumab (BIODESA)Rheumatoid arthritisISRCTN61158084niversity Hospital Regensburg (Universitätsklinikum Regensburg) (Germany)60
已完成
不适用
Active management of rheumatoid arthritis (RA)ISRCTN78142229Record Provided by the NHSTCT Register - 2004 Update - Department of Health (UK)100